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Abstract 
This report, based on data from a clinical case, proposes that pulmonary tumor thrombotic 
microangiopathy, an underdiagnosed cause of pulmonary hypertension and death in pa-
tients with adenocarcinoma, is a paraneoplastic syndrome (PNS). Clinicians in general must 
be alert to the presence or development of PNS that may precede, coincide with, follow, or 
herald the recurrence or the primary diagnosis of malignancy since early recognition facili-
tates prompt diagnosis and treatment. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Clinicians in general must be alert to the presence or development of paraneoplastic 
syndromes (PNS) that may precede, coincide with, follow, or herald the recurrence or the 
primary diagnosis of malignancy since early recognition facilitates prompt diagnosis and 
treatment. PNS is defined as a ‘pathology caused by tumor cells, which systematically pro-
duce a large amount of hormones, growth factors, cytokines and a variety of specific symp-
toms’ [1]. Examples of PNS, associated with metabolic, mucocutaneous, hormonal and neuro-
logical symptoms [2], include dermatomyositis-polymyositis, Cushing syndrome, carcinoid 
syndrome, myasthenia gravis and syndrome of inappropriate antidiuretic hormone [3]. To 
this list of distinct PNS we would add a rare, fatal and likely underdiagnosed cause of pulmo-
247 
 
Case Rep Oncol 2016;9:246–248 
DOI: 10.1159/000446064 
 
© 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cro 
Carter et al.: Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic 
Syndrome? 
 
 
 
nary hypertension known as pulmonary tumor thrombotic microangiopathy (PTTM) that is 
seen in patients with adenocarcinomas [4]. 
Case and Discussion 
Herein, we report a case of PTTM in a 47-year-old female with triple-negative breast 
cancer. Initially, this patient who developed fever and tachycardia during treatment on a 
clinical trial was hospitalized to rule out/treat infection. The next day she developed dys-
pnea, hypoxemia, and ground glass opacities on a CT scan. The lack of a response to broad-
spectrum antibiotics suggested an alternate diagnosis to pneumonia. On transthoracic echo-
cardiography, which was ordered over 1 week later, the cause of her dyspnea was revealed 
to be acute cor pulmonale. Together with an elevated D-dimer and a prolonged prothrombin 
time in the setting of a V/Q scan with a low probability for pulmonary embolism a diagnosis 
of PTTM, a rare arteriopathy associated with coagulation cascade activation and vascular 
remodeling [5] was made. 
Based on the pathogenesis of PTTM, which is related to the secretion of vascular remod-
eling factors [6] including vascular endothelial growth factor, fibroblast growth factor, and 
platelet-derived growth factor the plan was to treat the patient with sunitinib [7], a multitar-
geted tyrosine kinase inhibitor that blocks vascular endothelial growth factor and platelet-
derived growth factor receptors. While she unfortunately died before treatment with 
sunitinib could begin, it is reasonable to assume that earlier diagnosis and treatment would 
have resulted in a better outcome. 
Due to this paraneoplastic-like secretion of vascular and vascular smooth muscle mito-
gens, we suggest that PTTM meets the definition of a PNS. In the absence of a biopsy, echo-
cardiographic and coagulation studies [8] are the diagnostic tests of choice. 
As PTTM is a heretofore potentially unrecognized PNS, we suggest that the acute or sub-
acute development of cor pulmonale should prompt an evaluation for new, recurrent, or 
worsening malignancy. 
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